CEL SCI CORP

CEL-SCI Corporation is a clinical-stage biotechnology company focused on researching and developing immunotherapies to treat cancer and other diseases by activating the body's immune system. Its lead product candidate is Multikine, an investigational leukocyte interleukin injection intended as a first-line neoadjuvant treatment for adult patients with newly diagnosed, resectable locally advanced primary squamous cell carcinoma of the head and neck. Additionally, the company is developing product candidates based on its proprietary Ligand Epitope Antigen Presentation System technology for autoimmune conditions, including rheumatoid arthritis. Because its candidates are investigational and pending regulatory approval, CEL-SCI's customers primarily comprise commercial and distribution partners, clinical trial collaborators, and potential healthcare providers.

The company operates a dedicated manufacturing facility near Baltimore, Maryland, and clinical investigations across multiple phases have spanned approximately 740 patients across the United States, Canada, Europe, Israel, and Asia. Furthermore, CEL-SCI maintains commercialization and distribution partnerships covering regions such as Saudi Arabia, South Africa, and parts of Europe and Asia. The company's principal executive offices are located in Vienna, Virginia.

Summary of the business section of Cel Sci's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“The dollar value listed includes salary earned but not received and represents the base salary (cash and non-cash) earned. The officers have agreed to defer part of their salary for the years 2025 and 2024. As of September 30, 2025, CEL-SCI owed deferred salaries to the following employees: … 67”